Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederinvestor.lilly.com
Eli Lilly and Company News Releases
Get the latest updates from Eli Lilly and Company News Releases directly as they happen.
Follow now 227 followers
Latest posts
Last updated 2 days ago
Lilly reports Q3 2024 financial results highlighted by strong volume-driven revenue growth from New Products
2 days ago
Revenue in Q3 2024 increased 20%, driven by volume growth from Mounjaro...
Modified Titration of Donanemab Demonstrated Reduction of ARIA-E in Early Symptomatic Alzheimer's Disease Patients in Phase 3b study
3 days ago
A change in the initiation of donanemab dosing, shifting one vial of...
Lilly declares fourth-quarter 2024 dividend
4 days ago
INDIANAPOLIS , Oct. 28, 2024 /PRNewswire/ -- The board of directors of...
Lilly's mirikizumab is first and only IL23p19 antagonist to report long-term, multi-year, sustained efficacy and safety data for both ulcerative colitis and Crohn's disease
4 days ago
At three years, over 80% of patients with moderately to severely active...
Lilly's EBGLYSS™ (lebrikizumab-lbkz) demonstrated meaningful improvement in skin clearance and itch relief in the majority of patients with moderate-to-severe atopic dermatitis who discontinued dupilumab
7 days ago
In first dedicated study of a selective IL-13 inhibitor in patients previously...
Lilly's Kisunla™ (donanemab-azbt) Receives Marketing Authorization in Great Britain for the Treatment of Mild Cognitive Impairment and Mild Dementia Due to Alzheimer's Disease in Adult Patients Who Are Apolipoprotein E Ε4 Heterozygotes or Non-Carriers
9 days ago
Great Britain is the third major market where donanemab has received approval...
Lilly confirms date and conference call for third-quarter 2024 financial results announcement
16 days ago
INDIANAPOLIS , Oct. 16, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE...
Survey reveals 8 in 10 Americans with ulcerative colitis struggle to find a public restroom during emergencies
16 days ago
Results from Lilly's "Urgent Conversations" survey reinforce the work by the Crohn's...
Lilly reports one-year histologic outcomes in Phase 3 study of mirikizumab compared to ustekinumab for Crohn's disease
18 days ago
Data show more patients treated with mirikizumab achieved histologic response at Week...
Lilly appoints Thomas J. Fuchs as the company’s first chief AI officer
24 days ago
INDIANAPOLIS, Oct. 8, 2024— Today, Eli Lilly and Company (NYSE: LLY) announced...
Lilly announces new $4.5 billion site - the Lilly Medicine Foundry - to drive innovation in drug production and make medicines for clinical trials
30 days ago
Indiana facility will combine research, manufacturing and the latest technology to innovate...
New data show Lilly's EBGLYSS™ (lebrikizumab-lbkz) provided sustained disease control for up to three years in more than 80% of adults and adolescents with moderate-to-severe atopic dermatitis
about 1 month ago
Monthly EGBLYSS maintenance dosing sustained clear or almost-clear skin for up to...